Make VABYSMO your first choice for rapid* vision gains1,2
Mean BDVA change from baseline in treatment-naive eyes†1,2
FARETINA nAMD
FARETINA DME
*Nominal P-value <0.05 vs. baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline VA and ≥6 months of follow-up. Assessments were captured around the -6 to +7-day window around each injection visit.
VABYSMO delivers fast* drying after 1 injection in the real world1,2
Mean CST in treatment-naive eyes†1,2
FARETINA nAMD
FARETINA DME
*FARETINA-DME: Nominal P-value <0.05 vs baseline and FARETINA-AMD: Nominal P-value <0.01 vs baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline CST measurement (0–30 days before index) between 7 February 2022 and 30 June 2023, and 2+ CST measures in ≤180 days before index and 2+ CST in 180 days post index, excluding CST measurements ≤14 days after an injection. Statistical test for change in CST from baseline.
Most patients achieve early fluid resolution with VABYSMO3
Presence of fluid in treatment-naive eyes3
MOORFIELDS nAMD
Increase clinical capacity with VABYSMO’s extended durability1,2,4
Mean number of injections after 12 months of VABYSMO in treatment-naive eyes1,2
FARETINA nAMD
FARETINA DME
Make VABYSMO your first choice for rapid* vision gains1,2
Mean BDVA change from baseline in treatment-naive eyes†1,2
FARETINA nAMD
FARETINA DME
*Nominal P-value <0.01 vs. baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline VA and ≥6 months of follow-up. Assessments were captured around the -6 to +7-day window around each injection visit.
VABYSMO delivers fast* drying after 1 injection in the real world1,2
Mean CST in treatment-naive eyes†1,2
FARETINA nAMD
FARETINA DME
*Nominal P value <0.01 vs. baseline. P-values are nominal and not adjusted for multiplicity; no formal statistical conclusion should be made based on the P-values. †Among eyes with a baseline CST measurement (0–30 days before index) between February 7, 2022 and June 30, 2023, and 2+ CST measures in ≤180 days before index and 2+ CST in 180 days post index, excluding CST measurements ≤14 days after an injection. Statistical test for change in CST from baseline.
Most patients achieve early fluid resolution with VABYSMO3
Presence of fluid in treatment-naive eyes3
MOORFIELDS nAMD
Mean number of injections after 12 months of VABYSMO in treatment-naive eyes1,2
FARETINA nAMD
FARETINA DME
References
- Tabano D, et al. Presented at ARVO 2024, presentation available at medically.roche.com.
- Borkar D, et al. Presented at ARVO 2024, presentation available at medically.roche.com.
- Sing YS, et al. Presented at EURETINA 2023.
- Narayan A, et al. Presented at EURETINA 2023.
